SCHEMBL20090898

SCHEMBL20090898

O=C(OCc1ccccc1)S(=O)(=O)N1C[C@H](CN2CCOC2)Oc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
P2RX1 P51575 1/20 0.38
P2RX3 P56373 1/20 0.38
P2RX4 Q99571 1/20 0.38
SIGMAR1 Q99720 3/20 0.36
HTR1A P08908 2/20 0.36
ALDH1A1 P00352 4/20 0.35
POLB P06746 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
EGFR P00533 1/20 0.34
MAPT P10636 1/20 0.34
REN P00797 1/20 0.34
SIRT1 Q96EB6 1/20 0.34
ABCB1 P08183 1/20 0.34
USP2 O75604 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19879014 0.84 MEN1 (0.47) MEN1KMT2ANPSR1P2RX1P2RX3
SCHEMBL20086522 0.83 NAAA (0.37) MEN1KMT2ANPSR1P2RX1P2RX3
SCHEMBL19878977 0.83 P2RX4 (0.43) P2RX1P2RX3P2RX4POLBNPC1
SCHEMBL19878980 0.81 HTT (0.47) P2RX1P2RX3P2RX4ALDH1A1POLB
SCHEMBL20086502 0.80 RORC (0.41) NPSR1P2RX1P2RX3P2RX4ALDH1A1
SCHEMBL20086653 0.79 RORC (0.42) P2RX1P2RX3P2RX4SIRT1
SCHEMBL20086523 0.79 GSK3A (0.38) P2RX1P2RX3P2RX4ALDH1A1NPC1
SCHEMBL20086654 0.79 CYP19A1 (0.40) P2RX1P2RX3P2RX4
SCHEMBL20086495 0.79 RORC (0.42) P2RX1P2RX3P2RX4SIRT1
SCHEMBL20086493 0.79 CYP19A1 (0.40) P2RX1P2RX3P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-09-24 US disclosed
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE LYCERA CORPORATION 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE RORB, RORA, RORC MEN1 3786/4885KMT2A 1546/4885NPSR1 285/4885
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORB, RORA, RORC MEN1 4287/4885KMT2A 1579/4885NPSR1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.